CN114634483B - 用于治疗癌症和增殖性疾病的抗有丝分裂酰胺 - Google Patents

用于治疗癌症和增殖性疾病的抗有丝分裂酰胺 Download PDF

Info

Publication number
CN114634483B
CN114634483B CN202210190090.XA CN202210190090A CN114634483B CN 114634483 B CN114634483 B CN 114634483B CN 202210190090 A CN202210190090 A CN 202210190090A CN 114634483 B CN114634483 B CN 114634483B
Authority
CN
China
Prior art keywords
cancer
unsubstituted
substituted
mmol
reaction mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202210190090.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN114634483A (zh
Inventor
亚当·西迪基-耆那
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Frost Biologic Inc
Original Assignee
Frost Biologic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Frost Biologic Inc filed Critical Frost Biologic Inc
Priority to CN202210190090.XA priority Critical patent/CN114634483B/zh
Publication of CN114634483A publication Critical patent/CN114634483A/zh
Application granted granted Critical
Publication of CN114634483B publication Critical patent/CN114634483B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN202210190090.XA 2014-02-21 2015-02-20 用于治疗癌症和增殖性疾病的抗有丝分裂酰胺 Active CN114634483B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210190090.XA CN114634483B (zh) 2014-02-21 2015-02-20 用于治疗癌症和增殖性疾病的抗有丝分裂酰胺

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461942956P 2014-02-21 2014-02-21
US61/942,956 2014-02-21
CN202210190090.XA CN114634483B (zh) 2014-02-21 2015-02-20 用于治疗癌症和增殖性疾病的抗有丝分裂酰胺
CN201580009889.2A CN106068263A (zh) 2014-02-21 2015-02-20 用于治疗癌症和增殖性疾病的抗有丝分裂酰胺
PCT/US2015/016928 WO2015127284A2 (en) 2014-02-21 2015-02-20 Antimitotic amides for the treatment of cancer and proliferative disorders

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201580009889.2A Division CN106068263A (zh) 2014-02-21 2015-02-20 用于治疗癌症和增殖性疾病的抗有丝分裂酰胺

Publications (2)

Publication Number Publication Date
CN114634483A CN114634483A (zh) 2022-06-17
CN114634483B true CN114634483B (zh) 2024-08-13

Family

ID=52684675

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202210190090.XA Active CN114634483B (zh) 2014-02-21 2015-02-20 用于治疗癌症和增殖性疾病的抗有丝分裂酰胺
CN201580009889.2A Pending CN106068263A (zh) 2014-02-21 2015-02-20 用于治疗癌症和增殖性疾病的抗有丝分裂酰胺

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201580009889.2A Pending CN106068263A (zh) 2014-02-21 2015-02-20 用于治疗癌症和增殖性疾病的抗有丝分裂酰胺

Country Status (15)

Country Link
US (5) US10016398B2 (cg-RX-API-DMAC7.html)
EP (1) EP3107909B1 (cg-RX-API-DMAC7.html)
JP (1) JP6506313B2 (cg-RX-API-DMAC7.html)
KR (1) KR102420508B1 (cg-RX-API-DMAC7.html)
CN (2) CN114634483B (cg-RX-API-DMAC7.html)
AU (1) AU2015218775C1 (cg-RX-API-DMAC7.html)
BR (1) BR112016019161B1 (cg-RX-API-DMAC7.html)
CA (1) CA2940237C (cg-RX-API-DMAC7.html)
ES (1) ES2893374T3 (cg-RX-API-DMAC7.html)
IL (1) IL247293B (cg-RX-API-DMAC7.html)
MX (1) MX390530B (cg-RX-API-DMAC7.html)
RU (1) RU2713179C2 (cg-RX-API-DMAC7.html)
SG (2) SG10202000590SA (cg-RX-API-DMAC7.html)
WO (1) WO2015127284A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201606471B (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6420622B1 (en) 1997-08-01 2002-07-16 3M Innovative Properties Company Medical article having fluid control film
BR112016019161B1 (pt) * 2014-02-21 2022-12-20 Frost Biologic, Inc Amidas antimitóticas, composições farmacêuticas que as compreendem e uso das mesmas
CN106727583A (zh) * 2016-12-12 2017-05-31 范旭升 一种治疗舒张性心衰的药物组合物
US11377436B2 (en) * 2017-07-12 2022-07-05 The Brigham And Women's Hospital, Inc. EAAT2 enhancing molecules
US11760701B2 (en) 2018-02-27 2023-09-19 The Research Foundation For The State University Of New Yrok Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same
WO2025248483A1 (ko) * 2024-05-30 2025-12-04 삼진제약주식회사 Nr2f6 억제제 및 이의 용도

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0001930D0 (en) * 2000-01-27 2000-03-22 Novartis Ag Organic compounds
NZ522990A (en) * 2000-06-05 2003-08-29 Dong A Pharm Novel oxazolidinone derivatives and a process for the preparation thereof
US6995162B2 (en) * 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
GB0209715D0 (en) * 2002-04-27 2002-06-05 Astrazeneca Ab Chemical compounds
JP2008505145A (ja) * 2004-06-30 2008-02-21 ノバルティス アクチエンゲゼルシャフト 排出ポンプ阻害剤を用いてペプチドデホルミラーゼ阻害剤の感受性を増加するための方法
EP1921066A4 (en) * 2005-08-11 2010-07-07 Takeda Pharmaceutical Pyridylphenol compound and its use
AU2007211276B2 (en) * 2006-01-31 2013-06-06 Synta Pharmaceuticals Corp. Pyridylphenyl compounds for inflammation and immune-related uses
ATE524465T1 (de) 2006-11-17 2011-09-15 Glaxosmithkline Llc 2-carboxy-thiophen-derivate als viruzide
US20100130496A1 (en) * 2007-04-12 2010-05-27 F. Hoffmann-La Roche Ag Pyrimidine derivatives as inhibitors of phosphatidylinositol-3-kinase
WO2010039236A1 (en) * 2008-10-01 2010-04-08 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
WO2010100475A1 (en) * 2009-03-02 2010-09-10 Astrazeneca Ab Hydroxamic acid derivatives as gram-negative antibacterial agents
NZ598758A (en) * 2009-09-11 2013-12-20 Amgen Inc N-4 (-((3-(2-amino-4 pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer
JP6112486B2 (ja) * 2010-04-27 2017-04-12 カルシメディカ,インク. 細胞内カルシウムを調節する化合物
WO2011142151A1 (ja) * 2010-05-14 2011-11-17 シャープ株式会社 携帯型情報端末およびその制御方法
TWI541243B (zh) * 2010-09-10 2016-07-11 拜耳知識產權公司 經取代咪唑并嗒
JP2014503000A (ja) * 2011-01-21 2014-02-06 アッヴィ・インコーポレイテッド キナーゼのピコリンアミド阻害剤
US8748432B2 (en) * 2011-02-10 2014-06-10 Syngenta Participations Ag Microbiocidal pyrazole derivatives
EP2704701B1 (en) * 2011-05-03 2018-01-03 PRCL Research Inc. Compounds for inflammation and immune-related uses
US20140242099A1 (en) * 2011-10-28 2014-08-28 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
BR112016019161B1 (pt) * 2014-02-21 2022-12-20 Frost Biologic, Inc Amidas antimitóticas, composições farmacêuticas que as compreendem e uso das mesmas

Also Published As

Publication number Publication date
US10772872B2 (en) 2020-09-15
CA2940237C (en) 2023-03-07
IL247293A0 (en) 2016-09-29
JP6506313B2 (ja) 2019-04-24
JP2017506267A (ja) 2017-03-02
US20260034101A1 (en) 2026-02-05
US12383533B2 (en) 2025-08-12
KR102420508B1 (ko) 2022-07-13
MX390530B (es) 2025-03-20
RU2016135555A3 (cg-RX-API-DMAC7.html) 2018-10-05
WO2015127284A2 (en) 2015-08-27
SG11201606869TA (en) 2016-09-29
IL247293B (en) 2021-01-31
KR20160116009A (ko) 2016-10-06
ES2893374T3 (es) 2022-02-08
US10016398B2 (en) 2018-07-10
US20220008395A1 (en) 2022-01-13
CN114634483A (zh) 2022-06-17
MX2016010877A (es) 2017-05-04
SG10202000590SA (en) 2020-03-30
ZA201606471B (en) 2025-06-25
EP3107909B1 (en) 2021-07-14
WO2015127284A3 (en) 2015-10-15
BR112016019161B1 (pt) 2022-12-20
RU2713179C2 (ru) 2020-02-04
US20170172984A1 (en) 2017-06-22
AU2015218775B2 (en) 2019-06-20
RU2016135555A (ru) 2018-03-28
US11129813B2 (en) 2021-09-28
EP3107909A2 (en) 2016-12-28
BR112016019161A2 (cg-RX-API-DMAC7.html) 2017-08-15
CN106068263A (zh) 2016-11-02
CA2940237A1 (en) 2015-08-27
AU2015218775A1 (en) 2016-08-25
US20180325871A1 (en) 2018-11-15
AU2015218775C1 (en) 2020-01-16
US20200397758A1 (en) 2020-12-24

Similar Documents

Publication Publication Date Title
CN110003204B (zh) 一种bet蛋白抑制剂、其制备方法及用途
JP7033079B2 (ja) 芳香族スルホンアミド誘導体
US11129813B2 (en) Antimitotic amides for the treatment of cancer and proliferative disorders
CN104334529B (zh) 用于抑制abl1、abl2和bcr‑abl1的活性的化合物和组合物
WO2016026445A1 (zh) 作为fgfr激酶抑制剂的吲唑类化合物及其制备和应用
JP2014122161A (ja) ピラゾール化合物
WO2016088813A1 (ja) 新規ジアザビシクロ[2.2.2]オクタン誘導体
AU2016262642A1 (en) Substituted pyridazine carboxamide compounds as kinase inhibitor compounds
TW201817726A (zh) 3,4-二吡啶基吡唑類衍生物、其製備方法及其在醫藥上的應用
JP2001511798A (ja) オキシド−スクアレンシクラーゼ抑制剤として有用な複素環化合物
CN118434743A (zh) 三环杂环类
KR101920163B1 (ko) 항암용 약학 조성물
JP2008534506A (ja) 急性骨髄性白血病の治療又は予防法
CN113493414A (zh) 一种氘代取代丁烯酰胺及其制备方法与应用
CN104974104B (zh) 含噁唑的丙炔酰胺类衍生物及其制法和药物组合物与用途
KR20200102565A (ko) 피라졸로피리다진 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암 예방 또는 치료용 약학적 조성물
HK1232858B (en) Antimitotic amides for the treatment of cancer and proliferative disorders
CN103570616A (zh) N′-直链烷酰基邻吡啶酰肼衍生物及其制法和药物组合物与用途
TW200924754A (en) Pyrazinones as cellular proliferation inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant